Targeted agents in gastrointestinal cancer: a reality in clinical practice Eric Van Cutsem Editorial 04 April 2008 Pages: 57 - 57
What is the impact of biologicals in colorectal cancer? Rachel WongDavid Cunningham Review 15 March 2008 Pages: 59 - 69
The role of biologics in stomach cancer Florian LordickTobias SchulzeDirk Jäger Review 11 April 2008 Pages: 71 - 79
Rationale for targeted therapies in hepatocellular carcinoma Sandrine FaivreChantal DreyerEric Raymond Review 28 March 2008 Pages: 81 - 85
Can we predict the response to epidermal growth factor receptor targeted therapy? Philipp C. ManegoldGeorg LurjeHeinz-Josef Lenz Review 28 March 2008 Pages: 87 - 99
Imaging and targeted agents in gastrointestinal cancers: overview on perfusion- and diffusion-weighted magnetic resonance imaging and angiogenesis inhibitors Vincent VandecaveyeFrederik De KeyzerSteven Dymarkowski Review 15 March 2008 Pages: 101 - 110
A new functional imaging technique for the early functional evaluation of antiangiogenic treatment: dynamic contrast-enhanced ultrasonography (DCE-US) Nathalie LassauMohamed ChebilAlain Roche Review 05 April 2008 Pages: 111 - 117
Targeted therapies and surgical issues in gastrointestinal cancers Alexander A. ParikhLee M. Ellis Review 11 March 2008 Pages: 119 - 125
Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature Mauro MoroniSilvio VeroneseSalvatore Siena Day-to-Day Practice 11 March 2008 Pages: 127 - 130
